Bristol-Meyers Company v. Federal Trade Commission

598 F.2d 18, 194 U.S. App. D.C. 99
CourtCourt of Appeals for the D.C. Circuit
DecidedOctober 19, 1978
Docket77-1275
StatusPublished
Cited by44 cases

This text of 598 F.2d 18 (Bristol-Meyers Company v. Federal Trade Commission) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bristol-Meyers Company v. Federal Trade Commission, 598 F.2d 18, 194 U.S. App. D.C. 99 (D.C. Cir. 1978).

Opinions

BAZELON, Circuit Judge.

Bristol-Myers Company seeks disclosure of certain documents prepared by the Federal Trade Commission (FTC or Commission) in the course of an investigation and administrative enforcement proceeding concerning advertising claims made by manufacturers of nonprescription, internal analgesic drugs. The district court found that the information contained in these documents is protected by exemptions 5 and 7(A) of the Freedom of Information Act, 5 U.S.C. §§ 552(b)(5) and (7)(A) (1976), and granted summary judgment for the FTC. We remand to the district court for further proceedings.

I. BACKGROUND

Bristol-Myers is presently contesting a complaint issued by the FTC in February, 1973, charging that the company has falsely advertised Bufferin, Excedrin, and Excedrin P.M. in violation of sections 5 and 12 of the Federal Trade Commission Act, 15 U.S.C. §§ 45 and 52.1 Pursuant to the Commission’s regulations pertaining to discovery,2 Bristol-Myers has been able to gain access to various studies prepared by or for the FTC concerning consumer awareness and perceptions of analgesics products, and to scientific studies possessed by the FTC concerning the efficacy, speed of action, safety, and side effects of these products. Joint Appendix (J.A.) 121a-125a. Additionally, through resort to FOIA,3 the company has obtained from the Commission 3,160 documents, comprising 31,742 pages, relevant to the charges contained in the complaint. J.A. 114a.

In July, 1976, Bristol-Myers brought suit in the United States District Court for the District of Columbia for disclosure of 1300 documents withheld by the Commission. J.A. 10a-12a. During the course of the district court proceeding, however, the company withdrew its request for a substantial portion of these materials. J.A. 3a-4a, 267a, 283a. Still in dispute are 327 documents, comprising 765 pages. J.A. 4a.

In support of its motion for summary judgment, the Commission filed an indexed description of the information appearing in these 327 documents. J.A. 208a-223a. The index divides the documents into nine cate[22]*22gorfes,4 summarized by the Commission as follows:

CATEGORY A.
Inter-agency memoranda.
CATEGORY B.
100 “Blue Minutes,” i. e., reflections of the Commission’s deliberations.
CATEGORY C.
Documents from Commissioners.
CATEGORY D.
Interview reports (of expert witnesses).
CATEGORY E.
Correspondence between staff and consultants.
CATEGORY F.
One letter discussing a witness’ dissatisfaction with his compensation.
CATEGORY G. .
Drafts and comments (of proposed rules, notice orders, and complaints).
CATEGORY H.
Staff written reports of interviews by counsel.
CATEGORY I.
Memoranda from files of U.S. Pharmocopeial Convention.

The Commission also filed the affidavit of James H. Skiles, an attorney in the FTC’s Bureau of Consumer Protection who has been assigned to the adjudicative proceeding against Bristol-Myers. J.A. 112a-120a. The affidavit explains the Commission’s justifications for invoking exemptions 5 and 7(A) of FOIA.

It was on the basis of the index and accompanying affidavit that the district court granted summary judgment for the Commission.

II. ANALYSIS

The record establishes that the Commission voluntarily disclosed the overwhelming majority of the documents requested. Its index and affidavit, on the whole, describe with particularity the nature and contents of the documents withheld, as required by our decision in Vaughn v. Rosen, 157 U.S. App.D.C. 340, 484 F.2d 820 (1973), cert. denied, 415 U.S. 977, 94 S.Ct. 1564, 39 L.Ed.2d 873 (1974).

The withheld materials can be divided into two broad classes for purposes of analysis. The documents indexed in four Categories, A, B, C, and G, are all said to have been prepared by staff, individual Commissioners, or the Commission itself during the Commission’s process of deciding whether and how to proceed against analgesics manufacturers. Brief for the Commission at 32. The documents indexed in three Categories, D, E, and H, are all said to have been prepared by staff counsel and to contain communications, including interviews, with expert consultants contacted by the Commission during the analgesics investigation. Id.

A. “Predecisional” Memoranda

The district court found that the documents indexed in Categories A, B, C, and G are shielded from disclosure by exemption 5. This exemption permits an agency to withhold “inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency.” 5 U.S.C. § 552(b)(5).

The Commission contends that this result was correct insofar as Categories A, C and G are concerned because these memoranda are communications between and among FTC staff and Commissioners containing “advice, recommendations, opinions, analyses of potential trial or rule-making strategy and evaluations of evidence.” J.A. 114a.5 Relying on the Supreme Court’s decisions in Renegotiation Board v. Grumman Aircraft, 421 U.S. 168, 95 S.Ct. 1491, 44 L.Ed.2d 57 (1965) and NLRB v. Sears, Roe[23]*23buck & Co., 421 U.S. 132, 95 S.Ct. 1504, 44 L.Ed.2d 29 (1965), as well as our decision in Sterling Drug, Inc. v. FTC, 146 U.S.App. D.C. 237, 450 F.2d 698 (1971), the Commission argues that these documents are thus “predecisional” in character and must be protected in order to “prevent injury to the quality of agency decisions.” Brief for the Commission at 19-20 (quoting Sears, supra, 421 U.S. at 151, 95 S.Ct. 1516). The Commission contends that the documents listed in Category B — its so-called “Blue Minutes” —are similarly exempt as deliberative material under our decision in Ash Grove Cement Co. v. FTC, 167 U.S.App.D.C. 249, 250, 511 F.2d 815, 816, rehearing denied, 171 U.S.App.D.C. 285, 519 F.2d 934 (1975).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Awad v. Dr. Birbenk
N.D. California, 2023
A.B. v. U.S. Department of Justice
District of Columbia, 2021
United States v. Acquest Transit LLC
319 F.R.D. 83 (W.D. New York, 2017)
Sts Energy Partners Lp v. Federal Energy Regulatory Commission
82 F. Supp. 3d 323 (District of Columbia, 2015)
Aland v. Mead
2014 WY 83 (Wyoming Supreme Court, 2014)
Dorsen v. United States Securities & Exchange Commission
15 F. Supp. 3d 112 (District of Columbia, 2014)
Chesapeake Bay Foundation, Inc. v. U.S. Army Corps of Engineers
722 F. Supp. 2d 66 (District of Columbia, 2010)
Soter v. Cowles Pub. Co.
174 P.3d 60 (Washington Supreme Court, 2007)
Soter v. Cowles Publishing Co.
162 Wash. 2d 716 (Washington Supreme Court, 2007)
City of Colorado Springs v. White
967 P.2d 1042 (Supreme Court of Colorado, 1998)
Lurie v. Department of Army
970 F. Supp. 19 (District of Columbia, 1997)
Guy v. United Healthcare Corp.
154 F.R.D. 172 (S.D. Ohio, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
598 F.2d 18, 194 U.S. App. D.C. 99, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bristol-meyers-company-v-federal-trade-commission-cadc-1978.